Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Pharmacology

  • Article

    Safety of Diltiazem in Patients Taking Apixaban or Rivaroxaban

    March 4, 2025

    Clinical question: Does diltiazem increase the risk of major bleeding in patients on apixaban or rivaroxaban? Background: Diltiazem is a potent CYP3A4 inhibitor and a mild P-glycoprotein inhibitor....

  • Article

    Semaglutide Decreases Risk of Kidney Failure, Worsening of Kidney Disease, and Kidney-Related or Cardiovascular Death

    March 4, 2025

    Clinical question: Does treatment with semaglutide in patients with chronic kidney disease (CKD) and diabetes mellitus (DM) type II reduce the risk of kidney failure, progression of chronic kidney...

  • Article

    Understanding the Inflation Reduction Act’s Impact on Prescription Drug Costs

    February 3, 2025

    Prescription drug costs in the U.S. are among the highest in the world, surpassing those in other high-income nations by more than two and a half times. In 2023, the U.S. healthcare system’s total...

  • Article

    Inhaled Amikacin in the First 72 Hours of Mechanical Ventilation Reduced the Incidence of VAP

    January 1, 2025

    Clinical question: Does inhaled amikacin reduce the incidence of ventilator-associated pneumonia (VAP) in critically ill patients? Background: VAP is a common and serious complication in patients on...

  • Article

    90-Day Mortality Among Septic Patients Given Piperacillin-Tazobactam Versus Cefepime

    January 1, 2025

    Clinical question: In patients with undifferentiated sepsis without an indication for anaerobic coverage, is there increased mortality with the combined use of vancomycin/piperacillin-tazobactam...

  • Article

    Hydrocortisone Plus Fludrocortisone for CAP-Related Septic Shock

    January 1, 2025

    Clinical question: Does hydrocortisone and fludrocortisone reduce all-cause mortality among patients with septic shock due to community-acquired pneumonia (CAP)? Background: A meta-analysis of 17...

  • Article

    Empagliflozin After Acute Myocardial Infarction (EMPACT-MI)

    January 1, 2025

    Clinical question: Does starting empagliflozin for patients with acute myocardial infarction (AMI) and new onset systolic heart failure (HF) or congestive symptoms reduce the risk of first...

  • Article

    Illicit Medetomidine Use with Fentanyl

    January 1, 2025

    Medetomidine is a non-opioid veterinary anesthetic drug and a synthetic alpha-2-adrenoceptor agonist that is not approved for human use. Increasingly, it’s being used with illicitly manufactured...

  • Early Switch to Oral Antimicrobial Therapy for Staphylococcus aureus Bacteremia

    November 1, 2024

    Dr. Toy Clinical question: Is an early switch to oral antimicrobial therapy in low-risk Staphylococcus aureus bloodstream infection non-inferior to standard intravenous antimicrobial...

  • Article

    GLP-1 RA Use is Associated with Increased Residual Gastric Contents in Appropriately Fasted Patients Before Elective Procedures

    November 1, 2024

    Drr. Taylor Clinical question: Does Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) use lead to an increased risk of aspiration in patients undergoing anesthesia for elective...

Previous1 2 3 4 … 14Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences